News & Updates

Among women with obesity and atypical hyperplasia or low-risk endometrial cancer, weight loss during conservative management with intrauterine progestin improves treatment outcomes, according to a study.

In patients with small-cell lung cancer (SCLC), hippocampal avoidance-prophylactic cranial irradiation (HA-PCI) better preserves cognitive function and has no adverse impact on the incidence of brain metastases, overall survival (OS) and quality of life (QoL) compared with standard PCI, a phase III randomized controlled trial has shown.

Leaving out the use of external beam parametrial boost (EBPB) for locally advanced cervical cancer does not seem to negatively affect local control or survival in the era of image-guided brachytherapy, results of a study have shown. This then supports a reduced need for standardized use of parametrial boost.

Hepatic arterial infusion chemotherapy (HAIC) with fluorouracil, leucovorin and oxaliplatin (FOLFOX) as first-line treatment significantly improves overall survival (OS) vs transarterial chemoembolization (TACE) in patients with large, unresectable hepatocellular carcinoma (HCC), a phase III trial in China has shown.

Pembrolizumab extended recurrence-free survival (RFS) in patients with high-risk stage II melanoma who had undergone complete resection, interim analysis results of the phase III KEYNOTE-716 trial showed.

The COVID-19 pandemic has evidently affected the care and well-being of cancer patients, particularly those with advanced stages, reveals a recent study.

Individuals with long-term metabolic syndrome are at increased risk of developing gastrointestinal cancer overall, including colorectal and pancreatic cancers and hepatocellular carcinoma, with the risk increase independent of genetic predisposition, a study has found.

Local failure (LF) is more likely to occur in colorectal cancer (CRC) metastases treated with stereotactic ablative radiotherapy (SABR) if originating from right-sided primary CRC compared with left-sided, a study has found. In addition, LF rates are highest with liver metastases than other metastatic sites.

High-risk individuals who develop neoplastic progression to pancreatic cancer or high-grade dysplasia can present at an advanced stage despite showing no lesions during prior imaging surveillance evaluations, a new study has found.